Capital International Investors
NVCR icon

Capital International Investors’s NovoCure NVCR Stock Holding History

Capital International Investors’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-8,945,166
Closed -$159M – 464
2025
Q1 		$159M Buy
8,945,166
+71,264
+0.8% +$1.62M 0.03% 237
2024
Q4 		$264M Buy
8,873,902
+951,141
+12% +$20.1M 0.05% 208
2024
Q3 		$124M Sell
7,922,761
-3,773,587
-32% -$68.4M 0.02% 256
2024
Q2 		$200M Buy
11,696,348
+2,832,256
+32% +$49.8M 0.04% 219
2024
Q1 		$139M Buy
8,864,092
+2,221
+0% +$32.7K 0.03% 251
2023
Q4 		$132M Sell
8,861,871
-142,621
-2% -$1.91M 0.03% 256
2023
Q3 		$145M Buy
9,004,492
+195,560
+2% +$5.64M 0.04% 240
2023
Q2 		$366M Buy
8,808,932
+1,159,945
+15% +$72M 0.09% 187
2023
Q1 		$460M Sell
7,648,987
-302,661
-4% -$24.2M 0.12% 164
2022
Q4 		$583M Buy
7,951,648
+35,013
+0.4% +$2.63M 0.16% 144
2022
Q3 		$602M Buy
7,916,635
+1,470
+0% +$115K 0.18% 134
2022
Q2 		$550M Sell
7,915,165
-3,429,861
-30% -$258M 0.15% 149
2022
Q1 		$940M Buy
11,345,026
+13,021
+0.1% +$959K 0.21% 117
2021
Q4 		$851M Buy
11,332,005
+775,189
+7% +$77.8M 0.18% 128
2021
Q3 		$1.23B Buy
10,556,816
+1,413,074
+15% +$214M 0.28% 96
2021
Q2 		$2.03B Buy
9,143,742
+26,118
+0.3% +$5.08M 0.46% 58
2021
Q1 		$1.21B Buy
9,117,624
+862,354
+10% +$136M 0.3% 93
2020
Q4 		$1.43B Buy
8,255,270
+56,701
+0.7% +$7.76M 0.39% 74
2020
Q3 		$913M Buy
8,198,569
+4,710,881
+135% +$377M 0.28% 93
2020
Q2 		$207M Buy
3,487,688
+931,963
+36% +$61.3M 0.07% 207
2020
Q1 		$172M Buy
2,555,725
+1,175,050
+85% +$92.9M 0.07% 186
2019
Q4 		$116M Buy
1,380,675
+734,475
+114% +$59.3M 0.04% 222
2019
Q3 		$48.3M Hold
646,200
– – 0.02% 269
2019
Q2 		$40.9M Hold
646,200
– – 0.02% 290
2019
Q1 		$31.1M Buy
646,200
+318,900
+97% +$15.3M 0.01% 306
2018
Q4 		$11M Buy
+327,300
New +$12M 0.01% 340

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Capital International Investors's NVCR Position: Q2 2025 in Review

Capital International Investors sold out of NovoCure (NVCR) in Q2 2025, closing a stake of 8,945,166 shares — an estimated $159M sold.

Capital International Investors first reported a position in NVCR in Q4 2018 and held it in 26 quarters. The position peaked at $2.03B in Q2 2021. 243 funds tracked by Wall St. Rank hold NVCR as of Q2 2025.

  • Capital International Investors reported no remaining NovoCure position as of Q2 2025 after selling out during the quarter.
  • Capital International Investors sold 8,945,166 NovoCure shares in Q2 2025, an estimated $159M.
  • Capital International Investors first reported a position in NovoCure in Q4 2018 and held it in 26 quarters.
  • Capital International Investors's NovoCure position peaked at $2.03B in Q2 2021.
  • 243 funds tracked by Wall St. Rank held NovoCure as of Q2 2025.

Based on Capital International Investors's 13F filing for Q2 2025, filed 13 Aug 2025.